Immuron Ltd. retweetledi

Immuron CEO Steven Lydeamore outlines strategic pivot to partnering model for IMM-124E and IMM-529, targeting @ImmuronLtd $IMC profitability.
stockwirex.com/asx-stock-news…
English
Immuron Ltd.
826 posts

@ImmuronLtd
Publicly listed biopharma company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system & gut microbiome





















